Yes. It's not a simple matter of just exporting it. You would have to register it for sale in Canada, so you would have to go through the same process.
We were talking about red tape reduction. For example, there's a process that one goes through to be able to decide on simvastatin, for example, one of the statins for cholesterol, and it's two years to three years of government review of your dossier. That's after three or four years of the research that you've put in to try to support that application.
Then, when it hits the decision point and the lead investigators in the government say it's suitable for this switch and they need to remove it from their list of schedule F products--the list of prescription drugs--there's another whole two years' worth of the Canada Gazette, part I, the Canada Gazette, part II, and all of these machinations beyond when the decision is made, to eat up an extra two years of time and give your competitors that much more time to catch up to you. The standpoint we look at is that there are a number of regulatory issues that can assist, but even if all of them went away, we would still not eliminate that gap between Europe and Canada. We would just shrink it.